# CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models

Article · Odelaisy Leon-Triana, Soukaina Sabir, Gabriel F. Calvo, Juan Belmonte-Beitia, Salvador Chulian, Alvaro Martinez-Rubio, Maria Rosa, Antonio Perez-Martinez, Manuel Ramirez Orellana, Victor M. Perez-Garcia

- Archive id: arxiv:2003.10236
- Published: 2020-03-18
- Venue: Communications in Nonlinear Science and Numerical Simulation
- DOI: https://doi.org/10.1016/j.cnsns.2020.105570
- arXiv: https://arxiv.org/abs/2003.10236
- Citations: 52
- Source URL: https://arxiv.org/abs/2003.10236
- PDF: https://arxiv.org/pdf/2003.10236
- Provenance: arxiv

## Abstract

Immunotherapies use components of the patient immune system to selectively target cancer cells. The use of CAR T cells to treat B-cell malignancies --leukaemias and lymphomas-- is one of the most successful examples, with many patients experiencing long-lasting complete responses to this therapy. This treatment works by extracting the patient's T cells and adding them the CAR group, which enables them to recognize and target cells carrying the antigen CD19+, that is expressed in these haematological tumors. Here we put forward a mathematical model describing the time response of leukaemias to the injection of CAR T-cells. The model accounts for mature and progenitor B-cells, tumor cells, CAR T cells and side effects by incorporating the main biological processes involved. The model explains the early post-injection dynamics of the different compartments and the fact that the number of CAR T cells injected does not critically affect the treatment outcome. An explicit formula is found that provides the maximum CAR T cell expansion in-vivo and the severity of side effects. Our mathematical model captures other known features of the response to this immunotherapy. It also predicts that CD19+ tumor relapses could be the result of the competition between tumor and CAR T cells analogous to predator-prey dynamics. We discuss this fact on the light of available evidences and the possibility of controlling relapses by early re-challenging of the tumor with stored CAR T cells.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy), [Gene & Cell Therapy](https://space-kitty.com/topics/gene-cell-therapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.